SCHEMBL5758372

SCHEMBL5758372

CCn1c(SCc2noc(-c3cc(F)ccc3F)n2)nnc1-c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 10/20 0.49
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ATM Q13315 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544241 0.85 KMT2A (0.56) ALDH1A1SMN1; SMN2ATMKMT2ALMNA
SCHEMBL1543614 0.83 ALDH1A1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL1543774 0.83 SMN1; SMN2 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2ATM
SCHEMBL1544430 0.82 TSHR (0.41) OPRK1ALDH1A1SMN1; SMN2ATML3MBTL1
SCHEMBL5761187 0.81 MAPT (0.52) OPRK1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4951627 0.81 ALDH1A1 (0.47) OPRK1ALDH1A1NPSR1POLBLMNA
SCHEMBL1544291 0.81 KMT2A (0.43) NPC1RAB9AALDH1A1SMN1; SMN2ATM
SCHEMBL1543588 0.79 TSHR (0.47) ALDH1A1SMN1; SMN2ATMNPSR1KMT2A
SCHEMBL1544332 0.78 KMT2A (0.52) ALDH1A1SMN1; SMN2ATMNPSR1KMT2A
SCHEMBL1545016 0.77 KMT2A (0.51) ALDH1A1SMN1; SMN2ATMKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1723144-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2006-11-22 EP disclosed
WO-2006014185-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2006-02-09 WO disclosed